Kornimate/medical-research-clean huggingface dataset:
can gnrh agonist trigger prevent ovarian hyperstimulation syndrome?

Conditions: Ovarian Hyperstimulation Syndrome

Summary: ovarian hyperstimulation syndrome (ohss) is a major complication of ovarian stimulation for ivf if hcg is used to trigger final oocyte maturation. the investigators propose that using gnrh agonist as a trigger will eliminate ohss, even in high-risk patients.

administration of hcg (10.000 or 5.000 iu) is essential in ivf protocols to trigger final oocyte maturation after ovarian stimulation. in high responder patients with potential risk of developing ohss, hcg is usually withheld and the treatment cycle is cancelled without obtaining (cryopreserved) embryos for replacement. an alternative approach to trigger final oocyte maturation is to administer a gnrh agonist instead of hcg. this method is not possible following a long gnrh agonist protocol which causes down-regulation of the gnrh receptor. however, following gnrh antagonist treatment the gnrh receptor remains receptive to competitive binding by a gnrh agonist. it has been well-described in earlier ivf trials that a bolus of gnrh agonist will displace the gnrh antagonist from the gnrh receptors in the pituitary inducing an endogenous lh (and fsh) surge resulting in the maturation of oocytes and good quality embryos. in addition, the risk of moderate-to-severe ovarian hyperstimulation syndrome (ohss) becomes minimal due to the rapid demise of the corpora lutea. following luteolysis, fresh embryo transfer would require alternative luteal phase support to secure good clinical outcome. alternatively, good quality embryos obtained after gnrh agonist triggering can be cryopreserved and replaced in following frozen-thawn embryo transfer (ftet) cycles. thus, also eliminating late onset ohss due to pregnancy.

Eligibility criteria:
inclusion criteria: * a female patient who needs ivf to become pregnant. * regular menstrual cycle. * antral follicular count (afc) \> 18 * following treatment with follitropin beta more than 18 follicles ≥ 11 mm will develop. exclusion criteria: * hypersensitivity to the active substance or to any of the medications used. * tumors of the ovary, breast, uterus, pituitary or hypothalamus. * pregnancy. * abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. * primary ovarian failure. * ovarian cysts or enlarged ovaries. * a history of ovarian hyperstimulation syndrome (ohss). * a previous cos cycle that resulted in more than 30 follicles \> 11 mm measured by ultrasound examination. * fibroid tumours of the uterus incompatible with pregnancy. * malformations of the reproductive organs incompatible with pregnancy

Keywords: ovulation induction
bemiparin as a thromboprophylaxis after gynaecological surgeries

Conditions: Deep Vein Thrombosis (DVT); Pulmonary Embolism

Summary: the use of prophylaxis for venous thromboembolism (vte) remains grossly underused for women who undergo gynecologic surgery for benign conditions world wide and especially in developing countries including our region. having a research in our locality for the first time might raise awareness of the importance of vte prophylaxis.

deep vein thrombosis (dvt) and pulmonary embolism (pe), also referred to as venous thromboembolic events (vte), are two major complications after gynaecological surgeries that can result in significant morbidity and mortality. the incidence of vte after gynaecologic surgery varies depending on the method used for diagnosis. the rate of clinical dvt is estimated to be 3% after gynaecological surgery if no thromboprophylaxis was used. the rate of vte assumed to decrease to 0.4% if low molecular weight heparin was used as a thromboprophylaxis. according to our knowledge there are no published researches on the effect of the new second generation low molecular weight heparin bemiparin as a thromboprophylaxis after benign gynaecological surgery in comparison to a control group.

Eligibility criteria:
inclusion criteria: * female undergoing benign gynecological surgeries. * having moderate,high and very high risk factors for venous thromboembolism. * no contraindications for the use of heparin. exclusion criteria: * having mild risk factors for thromboembolism. * active vaginal bleeding. * thrombocytopaenia. * any patient who is already on anticoagulant. * sever renal or liver diseases.

Keywords: thromboprophylaxis bemiparin low molecular weight heparin major gynaecological surgeries benign gynaecological surgeries
to compare the efficacy and patient's satisfaction from pain management of women after cesarean section by pain relievers' administration in fix protocol compared to protocol following demand

Conditions: Pain Management; Cesarean Section

Summary: cesarean deliveries are prevalent. unlike other operations, quick recovery is required for the mother to nurture the newborn child and establishing an appropriate mother-child bonding. therefore, effective pain management is crucial. in this study we would like to compare between two pain relievers' administration protocols: (1) pain relievers' administration in fix protocol (type of medications, dose and intervals) or (2) pain relievers' administration following demand (the same type and doses, however, medications will be given only following patient's request). the primary outcome will be patient satisfaction, pain control and the necessity of additional medications (rescue doses). the protocols will be used for the first 48 hours following surgery.


Eligibility criteria:
inclusion criteria: * women that underwent cesarean section exclusion criteria: * women suffering from chronic pain * women using chronic pain medications * allergy to any drug used in the study * women underwent general anesthesia during the surgery * women with elevated liver enzymes

Keywords: pain management cesarean section
clinical trial for the comparative evaluation of acid suppression and symptom management of gastroesophageal reflux disease with the administration of tegoprazan or pantoprazole

Conditions: Gastroesophageal Reflux Disease

Summary: the objective of this clinical trial is to compare which of the two drugs best resolves symptoms in patients diagnosed with erosive and non-erosive gastroesophageal reflux disease, adult males and females. the main question is what is the proportion of patients with resolution of the main symptoms of gastroesophageal reflux disease at four weeks of treatment with pantoprazole vs tegoprazan.


Eligibility criteria:
inclusion criteria: * with endoscopic diagnosis of gerd or nerd (endoscopy ≤ 15 days old) * with positive impedance phmetry results (phmetry ≤ 15 days old) * with recurrent symptoms of heartburn and regurgitation for a previous period ≥ 3 months old exclusion criteria: * with known hypersensitivity to tegoprazan, pantoprazole, or any of the components of each formulation * subjects with concomitant administration of atazanavir, nelfinavir or rilpivirine * nephropathic and/or hepatopathic subjects (including non-alcoholic hepatitis) * subjects with upper gastrointestinal tract bleeding * subjects with gastric and/or duodenal ulcer 2 months prior to screening * subjects with a history of esophageal or gastric surgery

Keywords: gerd pantoprazole tegoprazan p-cab ppi
culinary spices in metabolic syndrome.

Conditions: Metabolic Syndrome

Summary: this double blind, placebo controlled randomized controlled trial aims to evaluate the effect of three commonly used culinary spices - ginger (zingiber officinale), cinnamon (cinnamomum) and black seed (nigella sativa) on the cardiometabolic parameters of individuals with risk factors of metabolic syndrome. participants consume their assigned treatment for 12 weeks, and key cardiovascular and glucometabolic parameters are recorded at baseline, week 6, and week 12 of the study.


Eligibility criteria:
inclusion criteria: * age (18-50 years) * 2 or more of mets diagnostic criteria: * high waist circumference (\>80 cm for female and \>94 cm for males), * elevated blood pressure (equal to or greater than 130/85 mm hg or use of medication for hypertension), * high fasting blood glucose (equal to or greater than 100 mg/dl \[5.6 mmol/l\] or use of medication for hyperglycemia), * lowered hdl cholesterol (less than 40 mg/dl \[1.03 mmol/l\] for men and less than 50 mg/dl \[1.29 mmol/l\] for women) and * increased triglycerides (equal to or greater than 150 mg/dl \[1.7 mmol/l\]). participants who had at least three risk factors out of five or had two risk factors and one borderline were included in the study. exclusion criteria * older than 50 years old or younger than 17 years old and * did not meet the metabolic syndrome diagnostic criteria * allergic to spices * current smokers * pregnant women * lactating women or * currently taking medication and if they * refused to provide blood sample. * acute illnesses * chronic diseases such as kidney, liver, cardiovascular and gastrointestinal diseases were excluded from the study
zd 1839 plus combination chemotherapy in treating patients with non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: some tumors need growth factors produced by the body's white blood cells to keep growing. zd 1839 may interfere with the growth factor and stop the tumor from growing. drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. it is not yet known whether chemotherapy is more effective with or without zd 1839 for non-small cell lung cancer. purpose: randomized phase iii trial to compare the effectiveness of combination chemotherapy with or without zd 1839 in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. compare the 1 year survival rate, time to worsening of disease related symptoms, and progression free survival in chemotherapy naive patients with stage iiib or iv non-small cell lung cancer treated with one of two doses of zd 1839 or placebo combined with gemcitabine and cisplatin. outline: this is a randomized, double blind, placebo controlled, multicenter study. patients are randomized to one of three treatment arms. patients receive gemcitabine and cisplatin combined with lower dose oral zd 1839 (arm i), higher dose oral zd 1839 (arm ii), or placebo (arm iii). projected accrual: a total of 1,029 patients (343 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically proven non-small cell lung cancer stage iii disease that is not curable with surgery or radiotherapy or stage iv disease chemotherapy naive patient characteristics: age: 18 and over performance status: 0-2 life expectancy: not specified hematopoietic: absolute neutrophil count at least 2,000/mm3 wbc at least 4,000/mm3 hepatic: alt and ast less than 2.5 times upper limit of normal (uln) (less than 5 times uln if liver metastasis present) bilirubin less than 1.25 times uln renal: creatinine less than 1.5 times uln creatinine clearance greater than 60 ml/min cardiovascular: no evidence of severe or uncontrolled cardiovascular disease pulmonary: no evidence of severe or uncontrolled pulmonary disease prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: no concurrent systemic endocrine therapy that is known to have an effect on non-small cell lung cancer radiotherapy: see disease characteristics prior localized irradiation allowed surgery: see disease characteristics prior surgery allowed other: no concurrent drugs with known significant cytochrome p450 3a4 inhibitory effects (e.g., ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil)

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
a phase i/iii study to evaluate efficacy, pk and safety between ct-p13 sc and ct-p13 iv in patients with active ra

Conditions: Rheumatoid Arthritis

Summary: this is a phase i/iii study to evaluate efficacy, pharmacokinetics and safety between ct-p13 sc and ct-p13 iv in patients with active rheumatoid arthritis (ra).

a new subcutaneous infliximab formulation is developed by celltrion, inc. as an alternative to the intravenous regimen where subcutaneous infliximab injection typically takes less than 2 minutes. the availability of a subcutaneous formulation of infliximab would increase the treatment options available to patients, particularly those wishing to self-administer their therapy. this phase i/iii study randomized, double-blinded (part 2 only), multicenter, parallel-group study was designed to evaluate efficacy, pharmacokinetics and safety between subcutaneous ct-p13 and intravenous ct-p13 in patients with active ra.

Eligibility criteria:
inclusion criteria: * patient is male or female between 18 and 75 years old, inclusive. * patient has a diagnosis of ra according to the 2010 american college of rheumatology (acr)/european league against rheumatism (eular) classification criteria for at least 6 months * patient has active disease as defined by the presence of 6 or more swollen joints (of 28 assessed), 6 or more tender joints (of 28 assessed) and serum c-reactive protein (crp) concentration \>0.6 mg/dl * patient who completed at least 3 months of treatment of oral or parenteral dosing with methotrexate between 12.5 to 25 mg/kg (between 10 to 25 mg/week in korea) and on stable dosing with methotrexate for at least 4 weeks prior to the first administration of the study drug. exclusion criteria: * patient who has previously received a biological agent for the treatment of ra and/or a tnfα inhibitor for the treatment of other disease * patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product * patient who had current or past history of chronic infection with hepatitis c or human immunodeficiency virus (hiv)-1 or -2 or current infection with hepatitis b * patient who had acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug. * patient who had an indeterminate result for interferon-γ release assay (igra) or latent tuberculosis (tb) at screening. for part 2, if igra result was indeterminate at screening, 1 retest was possible during the screening. if the repeated igra result was negative, the patient could be included in the study.
is transcutaneous carbon monoxide saturation of e-cigarette users comparable to that of smokers?

Conditions: Carbon Monoxide Poisoning

Summary: suspicions of carbon monoxide poisoning that lead to the treatment of victims are numerous. measurement of transcutaneous carbon monoxide saturation (spco) is a useful diagnostic and triage tool for victims and the toxic threshold is clearly defined for both non-smokers (spco\> 5%) and smokers ( spco\> 10%). currently, the use of e-cigarettes is democratizing. unfortunately, the threshold for toxic spco is not defined for this patient profile. the risk is treating in excess or worse than underestimating carbon monoxide poisoning in e-cigarette users who would be exposed to carbon monoxide exposure.


Eligibility criteria:
inclusion criteria: * patient presenting to adult emergency department * age ≥ 18 years exclusion criteria: * passive exposure to tobacco * mixed exposure (tobacco / e-cigarette) * patient having objected to the processing of his data

Keywords: carbon monoxide poisoning e-cigarette user transcutaneous saturation measurements
warfarin adverse event reduction for adults receiving genetic testing at therapy initiation (warfarin)

Conditions: Anti-coagulation Therapy; DVT; Pulmonary Embolism; Joint Surgery Multiple; Atrial Fibrillation; Prosthetic Replacement of Mitral Valve

Summary: the warfarin study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to warfarin.


Eligibility criteria:
inclusion criteria: 1. men and women at least 65 years old 2. beginning warfarin (0 - 3 doses of warfarin taken at the time of enrollment) for a variety of diseases or conditions that require at least 30 days oral anticoagulation with target inr ≥ 2.0 exclusion criteria: 1. unable to complete the study materials (questionnaires) with or without assistance (for example, those with dementia) 2. a previous genetically determined warfarin dose 3. the treating physician does not agree to use the recommended warfarin dose or feels that the patient should not be enrolled in the study

Keywords: warfarin genetic testing personalized medicine anti-coagulants coumadin
development of appetite measuring tool and appetite status of stunted children

Conditions: Nutritional Stunting

Summary: this study will provide a tool for researchers to measure important outcomes in relation to trial of intervention to reduce or prevent stunting. hypothesis: we assume that appetite score will be associated with improvement in growth and development parameters of children given the nutrition and psychosocial stimulation intervention objectives: to explore maternal perception regarding childhood stunting to develop and validate an appetite measuring tool to assess the appetite status of young children to examine the relationship between appetite score, growth and development, potential biomarkers of appetite, child food intake and intestinal inflammation of the children. methods: in the first phase, a qualitative study will be conducted to explore maternal perception regarding childhood stunting and to develop a tool- the "early childhood appetite and satiety tool"(ecast) using mixed method approach (qualitative and quantitative). in the second phase, a community-based trial will be conducted with 50 stunted children of aged 12-18 months, living in urban slums of dhaka, and 50 age-sex matched control children (non-stunted).

the stunted children will receive an intervention package which includes food supplementation (fs) with one egg and 150 ml of whole milk supplementing the usual home diet, 6 days a week for 3 months; psychosocial stimulation (ps) for 6 months, and routine clinical care monthly for 6 months. the control children will receive routine clinical care but no fs and ps. routine clinical care includes micronutrients powder, de-worming, health and nutrition education and immunization. all children will be assessed for appetite score (ecast score) and anthropometry-at baseline then monthly for 6 months; food intake at baseline then monthly for 3 months, and cognitive development using bayley scales of infant and toddler development, third version (bayley-iii) on enrolment and at 3 and 6 months of enrolment. blood samples will be collected to examine gut hormones, complete blood count and haemoglobin percentage. stool samples will be collected for routine examination and stool biomarkers. urine sample will be collected for screening urinary tract infection. all the specimens will be collected at baseline and at 3 and 6 months of enrollment. outcome measures/variables: the primary outcome: assessment of appetite score of stunted children aged 12-18 months compared to non-stunted children. the secondary outcomes are: -association of appetite score with growth and development with potential biomarkers of appetite with child food intake and intestinal inflammation of the children.

Eligibility criteria:
inclusion criteria: * 50 stunted children (laz\<-2) aged 12-18 months * 50 non-stunted (laz≥-2) aged 12-18 months exclusion criteria: * severe acute malnutrition (sam) * chronic illness * congenital anomaly/developmental delay/oromotor dysfunction

Keywords: appetite, stunting, satiety, children
sex difference effects on postoperative sleep, inflammation and cognition in patients undergoing general anesthesia

Conditions: Sex Differences; Postoperative Sleep Quality; Postoperative Pain; Inflammation Function; Postoperative Cognitive Function

Summary: video-assisted thoracoscopic surgery(vats) is among the most common and disabling persistent pain and inflammation conditions, with increasing prevalence in the developed world, and affects women to a greater degree than men. and sleep disruption also remains a challenging problem in surgical settings. postoperative sleep disturbances (posd) are defined as changes in the sleep structure and quality of patients during the early stages after surgery, which are manifested as significantly shortened rapid eye movement (rem) sleep, prolonged awake time, and sleep fragmentation. long-term posd may increase the risk of postoperative delirium or cognitive dysfunction and delay recovery, thereby worsening the patient's physical condition. the aim of the study was to investigate the effect of sex differences on postoperative pain, inflammation, sleep quality and cognitive function among patients who have undergone video-assisted thoracoscopic surgery under general anesthesia.


Eligibility criteria:
inclusion criteria: * 18-75 years old * asa i-iii * under general anesthesia exclusion criteria: * patients with central nervous system and mental diseases; * patients with preoperative sleep disturbances; * patients with a history of sedative, analgesic, or antidepression drug use; * patients with sleep apnea or moderate and severe obstructive sleep apneahypopnea syndrome;
efficacy study of antiemetics to reduce postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: we randomized patients who received laparoscopic surgery for benign gynecologic disease into double dose (experimental group) or single dose (control group) of antiemetics. we compared the degree of postoperative nausea and vomiting in experimental and control groups.


Eligibility criteria:
inclusion criteria: * laparoscopy for benign gynecologic disease exclusion criteria: * vomiting within 24 hours before surgery * not using patient controlled analgesics postoperatively
high flow nasal therapy in covid 19 patient

Conditions: High Flow Nasal Therapy

Summary: this study aims to to identify factors that predict success of high flow nasal therapy in covid19 patients .

coronavirus disease 2019 (covid-19) is a potentially fatal infection caused by the novel severe acute respiratory syndrome coronavirus-2 (sars-cov-2)\[1\]. the highly contagious nature and exponential spread of sars-cov-2, coupled with its potential for a rapid progressto acute respiratory distress syndrome (ards), has overwhelmed health care systems globally, contributing to the high mortality rates in early reports \[1,2\]. the initial approach for respiratory support for severe covid-19 pneumonia centredaround invasive mechanical ventilation and the standard lung protective strategy recommended for ards\[3\]. this may have been detrimental to a proportion of patients due to ventilator induced lung injury (vili) and associated systemic inflammation\[4\]. furthermore, other strategies to improve oxygenation may be more appropriate in patients with hypoxemic respiratory failure who do not require ventilatorysupport\[4\]. high-flow nasal oxygen (hfno) is delivered by an air/oxygen blender, an active humidifier, a single heated circuit, and a nasal interface. it delivers adequately heated and humidified medical gas at flow-rates of up to 60l/min, and is considered to have a number of physiological benefits, including the reduction of anatomical dead space and work of breathing, the provision of a constant fraction of inspired oxygen with adequate humidification and a degree of positive end-expiratory pressure (peep) \[5,6\].

Eligibility criteria:
inclusion criteria: * all patients above 18 y old that will be diagnosed as covid 19 based on pcr testing, who fulfil criteria that indicate need for high flow nasal therapy. exclusion criteria: * o children less than 18 y old * oropharyngeal and nasopharyngeal swap negative patients * patients who will refuse inclusion in the study